Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T16:26:08.326Z.
Calculation as of: 2026-10-06T16:26:08.326Z.
Quote observation: 2026-10-06T16:25:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bae8dd55c1776b4784265b7d6b815fecf0da21712464e51122872d0292d60ac3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$3.51B
PS Ratio
15.00
TTM Avg
44.87
3Y Avg
169.56
5Y Avg
109.21
Market Cap
$3.43B
PS Ratio
2892.21
TTM Avg
5949.66
3Y Avg
5949.66
5Y Avg
2255.37
Market Cap
$3.59B
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.11B
PS Ratio
864.01
TTM Avg
1171.95
3Y Avg
915.38
5Y Avg
373.66
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Celcuity Inc. (CELC) | $3.49B | N/A | N/A | N/A | N/A |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.51B | 15.00 | 44.87 | 169.56 | 109.21 |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.53B | 4.28 | 6.09 | 6.09 | 7.49 |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.43B | 2892.21 | 5949.66 | 5949.66 | 2255.37 |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.41B | 3.00 | 3.85 | 3.95 | 5.00 |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.59B | N/A | N/A | N/A | N/A |
| CareDx, Inc (CDNA)vs › | $3.37B | 7.36 | 3.47 | 3.09 | 3.52 |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.34B | N/A | N/A | N/A | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.11B | 864.01 | 1171.95 | 915.38 | 373.66 |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.04B | N/A | 1.30 | 815.49 | 815.49 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-13 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-26 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-14 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-13 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
